Table 4.

Multivariate analyses of the association of treatment delay intervals with OS and CSS

Tumor		Subgroupc	OS		CSS
			HRa (95% CI)	P-value	HRb(95% CI)	P-value
Serous	Stage I/II	Intermediate-delay	1.20(0.97,1.47)	0.094	1.09(0.85,1.40)	0.508
		Long-delay	2.65(1.40,5.01)	0.003	2.41(1.13,5.17)	0.023
	Stage III/IV	Intermediate-delay	1.09(1.04,1.15)	<0.001	1.09(1.03,1.15)	0.002
		Long-delay	1.07(0.91,1.25)	0.396	1.09(0.92,1.29)	0.332
Mucinous	Stage I/II	Intermediate-delay	1.28(0.75,2.18)	0.367	1.68(0.84,3.35)	0.144
		Long-delay	2.44(0.86,6.91)	0.092	2.04(0.47,8.87)	0.344
	Stage III/IV	Intermediate-delay	1.01(0.71,1.44)	0.941	0.85(0.55,1.29)	0.444
		Long-delay	0.37(0.13,1.09)	0.073	0.48(0.14,1.66)	0.246
Endometrioid	Stage I/II	Intermediate-delay	1.11(0.74,1.65)	0.618	1.41(0.84,2.37)	0.192
		Long-delay	2.10(0.76,5.77)	0.151	1.63(0.22,11.91)	0.632
	Stage III/IV	Intermediate-delay	1.07(0.80,1.42)	0.664	0.94(0.67,1.32)	0.720
		Long-delay	1.31(0.55,3.13)	0.536	0.80(0.24,2.67)	0.716
Clear	Stage I/II	Intermediate-delay	1.87(1.28,2.73)	0.001	1.91(1.23,2.96)	0.004
		Long-delay	2.44(0.74,8.05)	0.144	2.69(0.63,11.42)	0.180
	Stage III/IV	Intermediate-delay	1.11(0.84,1.45)	0.461	1.28(0.97,1.70)	0.081
		Long-delay	0.49(0.21,1.15)	0.102	0.60(0.25,1.40)	0.236
Other epithelial	Stage I/II	Intermediate-delay	1.40(0.83,2.35)	0.208	0.80(0.38,1.69)	0.558
		Long-delay	1.18(0.16,8.82)	0.872	2.01(0.26,15.59)	0.502
	Stage III/IV	Intermediate-delay	1.04(0.89,1.21)	0.648	1.06(0.90,1.26)	0.488
		Long-delay	0.77(0.47,1.25)	0.290	0.72(0.41,1.27)	0.261
Non-epithelial	Stage I/II	Intermediate-delay	1.01(0.50,2.04)	0.977	0.80(0.31,2.04)	0.636
		Long-delay	1.20(0.28,5.17)	0.802	1.54(0.33,7.11)	0.582
	Stage III/IV	Intermediate-delay	1.31(0.95,1.82)	0.104	1.49(1.03,2.16)	0.032
		Long-delay	0.71(0.35,1.44)	0.342	0.87(0.39,1.93)	0.732

HR^a: compared with immediate-treatment initiation

HR^b: compared with immediate-treatment initiation

Subgroup^c: immediate: < 1 month, intermediate-delay: 1-2 months, and long-delay: ≥3 months